Logo image of PRAH

Pra Health (PRAH) Stock Fundamental Analysis

NASDAQ:PRAH - Nasdaq -

165.21  -2.8 (-1.67%)

After market: 166.01 +0.8 (+0.48%)

Fundamental Rating

2

Taking everything into account, PRAH scores 2 out of 10 in our fundamental rating. PRAH was compared to 56 industry peers in the Life Sciences Tools & Services industry. PRAH has a bad profitability rating. Also its financial health evaluation is rather negative. PRAH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRAH was profitable.

1.2 Ratios

Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 10.03%
PM (TTM) 6.4%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

PRAH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 3.56 indicates that PRAH is not in any danger for bankruptcy at the moment.
PRAH has a Debt/Equity ratio of 0.74. This is a neutral value indicating PRAH is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 3.56
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.21 indicates that PRAH should not have too much problems paying its short term obligations.
PRAH has a Quick Ratio of 1.21. This is a normal value and indicates that PRAH is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21

More info and screens

5

3. Growth

3.1 Past

The earnings per share for PRAH have decreased by -1.36% in the last year.
PRAH shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.06% yearly.
Looking at the last year, PRAH shows a small growth in Revenue. The Revenue has grown by 6.57% in the last year.
Measured over the past years, PRAH shows a quite strong growth in Revenue. The Revenue has been growing by 14.55% on average per year.
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%

3.2 Future

Based on estimates for the next years, PRAH will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.49% on average per year.
PRAH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.45% yearly.
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PRAH Yearly Revenue VS EstimatesPRAH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B
PRAH Yearly EPS VS EstimatesPRAH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 32.65 indicates a quite expensive valuation of PRAH.
PRAH's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.62.
A Price/Forward Earnings ratio of 23.77 indicates a rather expensive valuation of PRAH.
PRAH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.70.
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
PRAH Price Earnings VS Forward Price EarningsPRAH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.96
PRAH Per share dataPRAH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PRAH's earnings are expected to grow with 16.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.12
PEG (5Y)1.71
EPS Next 2Y20.83%
EPS Next 3Y16.62%

More info and screens

0

5. Dividend

5.1 Amount

PRAH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Pra Health

NASDAQ:PRAH (6/30/2021, 8:12:54 PM)

After market: 166.01 +0.8 (+0.48%)

165.21

-2.8 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change-99.98%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.70B
Analysts60
Price Target171.11 (3.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
P/S 3.21
P/FCF N/A
P/OCF N/A
P/B 6.88
P/tB N/A
EV/EBITDA 23.96
EPS(TTM)5.06
EY3.06%
EPS(NY)6.95
Fwd EY4.21%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS51.45
BVpS24.02
TBVpSN/A
PEG (NY)1.12
PEG (5Y)1.71
Profitability
Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 10.03%
PM (TTM) 6.4%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z 3.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A